Literature DB >> 1068195

A surface antigen influenza vaccine. 1. Purification of haemagglutinin and neuraminidase proteins.

M I Brady, I G Furminger.   

Abstract

Influenza virus was centrifuged in a KII rotor through a sucrose gradient containing Triton N101, a non-ionic surfactant. The micelles of surfactant formed a band in the gradient. As virus particles passed through the surfactant, the haemagglutinin and neuraminidase proteins were stripped from the surface and remained near the surfactant micelles. The residual virus particles sedimented into a denser region of the gradient and were thus separated from the haemagglutinin and neuraminidase antigens. Fractions containing the surface antigens were pooled and Triton was removed by phase-separation at the cloud point.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1068195      PMCID: PMC2129851          DOI: 10.1017/s002217240002458x

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  26 in total

1.  A surface antigen influenza vaccine. 2. Pyrogenicity and antigenicity.

Authors:  M I Brady; I G Furminger
Journal:  J Hyg (Lond)       Date:  1976-10

2.  Induction of partial immunity to influenza by a neuraminidase-specific vaccine.

Authors:  R B Couch; J A Kasel; J L Gerin; J L Schulman; E D Kilbourne
Journal:  J Infect Dis       Date:  1974-04       Impact factor: 5.226

3.  The characterization of subviral particles derived from influenza virus.

Authors:  J J Skehel
Journal:  Virology       Date:  1971-05       Impact factor: 3.616

4.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses.

Authors:  D Hobson; R L Curry; A S Beare; A Ward-Gardner
Journal:  J Hyg (Lond)       Date:  1972-12

5.  Characterization of the ribonucleoprotein and neuraminidase of influenza A viruses by immunodiffusion.

Authors:  G C Schild; H G Pereira
Journal:  J Gen Virol       Date:  1969-04       Impact factor: 3.891

6.  Related studies of a recombinant influenza-virus vaccine. I. Derivation and characterization of virus and vaccine.

Authors:  E D Kilbourne; J L Schulman; G C Schild; G Schloer; J Swanson; D Bucher
Journal:  J Infect Dis       Date:  1971-11       Impact factor: 5.226

7.  The effect of nonaqueous solvents on the quaternary structure of viruses: a procedure for the simultaneous concentration, purification and disruption of influenza viruses.

Authors:  A R Neurath; B A Rubin; J Sillaman; H Tint
Journal:  Microbios       Date:  1971-09

8.  A quantitative, single-radial-diffusion test for immunological studies with influenza virus.

Authors:  G C Schild; M Henry-Aymard; H G Pereira
Journal:  J Gen Virol       Date:  1972-08       Impact factor: 3.891

9.  Crystalline antigen from the influenza virus envelope.

Authors:  C M Brand; J J Skehel
Journal:  Nat New Biol       Date:  1972-08-02

10.  Neuraminidase and resistance to vaccination with live influenza A2 Hong Kong vaccines.

Authors:  A N Slepushkin; G C Schild; A S Beare; S Chinn; D A Tyrrell
Journal:  J Hyg (Lond)       Date:  1971-12
View more
  18 in total

1.  A surface antigen influenza vaccine. 2. Pyrogenicity and antigenicity.

Authors:  M I Brady; I G Furminger
Journal:  J Hyg (Lond)       Date:  1976-10

Review 2.  Traditional and new influenza vaccines.

Authors:  Sook-San Wong; Richard J Webby
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

3.  Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens.

Authors:  A Bacon; J Makin; P J Sizer; I Jabbal-Gill; M Hinchcliffe; L Illum; S Chatfield; M Roberts
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  Reactogenicity and immunogenicity of a surface-antigen-adsorbed influenza virus vaccine in children.

Authors:  L M Eastwood; R Jennings; R D Milner; C W Potter
Journal:  J Clin Pathol       Date:  1979-06       Impact factor: 3.411

5.  Antibody response and persistence in volunteers following immunization with varying dosages of a trivalent surface antigen influenza virus vaccine.

Authors:  R Jennings; T L Smith; A R Mellersh; A Clark; R C Spencer; C W Potter
Journal:  J Hyg (Lond)       Date:  1985-02

6.  Use of the enzyme-linked immunosorbent assay (ELISA) for the estimation of serum antibodies in an influenza virus vaccine study.

Authors:  R Jennings; T Smith; C W Potter
Journal:  Med Microbiol Immunol       Date:  1981       Impact factor: 3.402

7.  The effect of bacterial peptidoglycans on the immune response of hamsters to influenza virus vaccines.

Authors:  C R Crawford; R Jennings; N Bradford; C W Potter
Journal:  Clin Exp Immunol       Date:  1982-06       Impact factor: 4.330

8.  Responses of volunteers to inactivated influenza virus vaccines.

Authors:  R Jennings; C W Potter; P M Massey; B I Duerden; J Martin; A M Bevan
Journal:  J Hyg (Lond)       Date:  1981-02

9.  Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents.

Authors:  H Glathe; W Lange
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

10.  A comparison of live and inactivated influenza A (H1N1) virus vaccines. 1. Short-term immunity.

Authors:  A Clark; C W Potter; R Jennings; J P Nicholl; A F Langrick; G C Schild; J M Wood; D A Tyrrell
Journal:  J Hyg (Lond)       Date:  1983-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.